HC Wainwright Reiterates "Buy" Rating for Dynavax Technologies (NASDAQ:DVAX)

HC Wainwright restated their buy rating on shares of Dynavax Technologies (NASDAQ:DVAX - Free Report) in a report published on Friday morning,Benzinga reports. They currently have a $29.00 price target on the biopharmaceutical company's stock.

Separately, The Goldman Sachs Group decreased their price target on shares of Dynavax Technologies from $20.00 to $15.00 and set a "neutral" rating for the company in a research report on Thursday, August 8th.

Dynavax Technologies Trading Up 8.2 %

NASDAQ DVAX traded up $0.99 during mid-day trading on Friday, reaching $13.01. 5,095,989 shares of the stock were exchanged, compared to its average volume of 2,115,563. The stock has a market capitalization of $1.70 billion, a PE ratio of 102.62 and a beta of 1.34. The company has a debt-to-equity ratio of 0.35, a quick ratio of 13.18 and a current ratio of 14.18. Dynavax Technologies has a 1-year low of $9.74 and a 1-year high of $15.01. The business's fifty day simple moving average is $11.13 and its 200 day simple moving average is $11.24.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last announced its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $0.08 EPS for the quarter, beating analysts' consensus estimates of $0.06 by $0.02. Dynavax Technologies had a return on equity of 2.76% and a net margin of 6.88%. The business had revenue of $73.80 million during the quarter, compared to the consensus estimate of $76.92 million. During the same quarter in the previous year, the business earned $0.03 earnings per share. On average, research analysts anticipate that Dynavax Technologies will post 0.16 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in DVAX. Kynam Capital Management LP boosted its position in Dynavax Technologies by 180.0% in the 1st quarter. Kynam Capital Management LP now owns 4,239,780 shares of the biopharmaceutical company's stock valued at $52,616,000 after buying an additional 2,725,397 shares during the last quarter. Millennium Management LLC acquired a new stake in Dynavax Technologies during the 2nd quarter valued at approximately $17,615,000. Great Point Partners LLC grew its stake in Dynavax Technologies by 87.7% during the 2nd quarter. Great Point Partners LLC now owns 2,374,000 shares of the biopharmaceutical company's stock valued at $26,660,000 after purchasing an additional 1,109,080 shares in the last quarter. Assenagon Asset Management S.A. purchased a new stake in Dynavax Technologies during the 3rd quarter worth approximately $8,291,000. Finally, Mizuho Markets Americas LLC boosted its stake in shares of Dynavax Technologies by 37.9% during the 2nd quarter. Mizuho Markets Americas LLC now owns 1,175,107 shares of the biopharmaceutical company's stock valued at $13,196,000 after buying an additional 323,050 shares during the last quarter. 96.96% of the stock is currently owned by hedge funds and other institutional investors.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.